ASCLETIS-B (01672) to Present Multiple Program Data at 33rd European Congress on Obesity (ECO 2026)

Stock News

05/06

ASCLETIS-B (01672) announced that it will present multiple programs via poster presentations at the 33rd European Congress on Obesity (ECO 2026), scheduled to take place in Istanbul, Turkey, from May 12 to May 15, 2026. The presentations will include a poster on Phase I data for ASC47, a fat-targeting thyroid hormone receptor beta (THRβ) agonist designed for weight loss without muscle reduction. In combination with semaglutide, ASC47 demonstrated a relative improvement in weight reduction of up to 111.8% compared to semaglutide monotherapy in obese subjects. Additionally, a poster on preclinical data for ASC36, a once-monthly next-generation amylin receptor agonist peptide, will be presented. In non-human primate models, ASC36 showed a mean apparent half-life of 32 days, which is six times longer than that of petrelintide. In a diet-induced obesity (DIO) rat model, ASC36 exhibited a relative improvement in weight reduction of 91% compared to petrelintide.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1174217966"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1174217966\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1174217966?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 08:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174217966","market":"hk","top_or_hot":-1,"title":"ASCLETIS-B (01672) to Present Multiple Program Data at 33rd European Congress on Obesity (ECO 2026)","media":"Stock News","content":"<p>ASCLETIS-B (01672) announced that it will present multiple programs via poster presentations at the 33rd European Congress on Obesity (ECO 2026), scheduled to take place in Istanbul, Turkey, from May 12 to May 15, 2026. The presentations will include a poster on Phase I data for ASC47, a fat-targeting thyroid hormone receptor beta (THRβ) agonist designed for weight loss without muscle reduction. In combination with semaglutide, ASC47 demonstrated a relative improvement in weight reduction of up to 111.8% compared to semaglutide monotherapy in obese subjects. Additionally, a poster on preclinical data for ASC36, a once-monthly next-generation amylin receptor agonist peptide, will be presented. In non-human primate models, ASC36 showed a mean apparent half-life of 32 days, which is six times longer than that of petrelintide. In a diet-induced obesity (DIO) rat model, ASC36 exhibited a relative improvement in weight reduction of 91% compared to petrelintide.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ASCLETIS-B (01672) to Present Multiple Program Data at 33rd European Congress on Obesity (ECO 2026)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nASCLETIS-B (01672) to Present Multiple Program Data at 33rd European Congress on Obesity (ECO 2026)\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-05-06 08:20</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>ASCLETIS-B (01672) announced that it will present multiple programs via poster presentations at the 33rd European Congress on Obesity (ECO 2026), scheduled to take place in Istanbul, Turkey, from May 12 to May 15, 2026. The presentations will include a poster on Phase I data for ASC47, a fat-targeting thyroid hormone receptor beta (THRβ) agonist designed for weight loss without muscle reduction. In combination with semaglutide, ASC47 demonstrated a relative improvement in weight reduction of up to 111.8% compared to semaglutide monotherapy in obese subjects. Additionally, a poster on preclinical data for ASC36, a once-monthly next-generation amylin receptor agonist peptide, will be presented. In non-human primate models, ASC36 showed a mean apparent half-life of 32 days, which is six times longer than that of petrelintide. In a diet-induced obesity (DIO) rat model, ASC36 exhibited a relative improvement in weight reduction of 91% compared to petrelintide.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"製藥","start_time":0,"source_url":"","article_id":"1174217966","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174217966","pubTimestamp":1778026854,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ASCLETIS-B (01672) announced that it will present multiple programs via poster presentations at the 33rd European Congress on Obesity (ECO 2026), scheduled to take place in Istanbul, Turkey, from May...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","BK1515":"抗疫概念","BK1161":"生物科技","ECO":"Okeanis Eco Tankers","BK1574":"生物医药B类股","01672":"歌礼制药-B","LU0997586861.USD":"FIDELITY NORDIC \"A\" (USDHDG) ACC","BK4144":"石油与天然气的储存和运输","01477":"欧康维视生物-B"},"translate_title":"歌礼-B(01672)将在第33届欧洲肥胖大会(ECO 2026)上展示多个项目数据","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ECO":1,"01672":1,"01477":1},"content_text":"ASCLETIS-B (01672) announced that it will present multiple programs via poster presentations at the 33rd European Congress on Obesity (ECO 2026), scheduled to take place in Istanbul, Turkey, from May 12 to May 15, 2026. The presentations will include a poster on Phase I data for ASC47, a fat-targeting thyroid hormone receptor beta (THRβ) agonist designed for weight loss without muscle reduction. In combination with semaglutide, ASC47 demonstrated a relative improvement in weight reduction of up to 111.8% compared to semaglutide monotherapy in obese subjects. Additionally, a poster on preclinical data for ASC36, a once-monthly next-generation amylin receptor agonist peptide, will be presented. In non-human primate models, ASC36 showed a mean apparent half-life of 32 days, which is six times longer than that of petrelintide. In a diet-induced obesity (DIO) rat model, ASC36 exhibited a relative improvement in weight reduction of 91% compared to petrelintide.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}